contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioporto-pronephro-akitm-ngal-kommercielt-tilgaengelig-i-usa

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

BioPorto

Bioporto meddelelte i dag den 28. august 2025 at ProNephro AKI (NGAL) nu officielt er kommercielt tilgængelig på laboratorier i USA gennem selskabets samarbejde med Roche Diagnostics. Testen er godkendt (FDA 510(k)) til brug på Roche’s cobas® c 501-analysatorer, som er bredt anvendt på hospitaler og kliniske laboratorier

Selskabet meddelte den 27. juni, at de havde modtaget den f&#xf8;rste ordre fra Roche p&#xe5; ProNephro AKI (NGAL) til b&#xf8;rn og unge i USA &#x2013; en klar milep&#xe6;l i selskabets kommercialisering af testen.
Bioporto meddelelte i dag den 28. august 2025 at ProNephro AKI (NGAL) nu officielt er kommercielt tilg&#xe6;ngelig p&#xe5; laboratorier i USA gennem selskabets samarbejde med Roche Diagnostics. Testen er godkendt (FDA 510(k)) til brug p&#xe5; Roche&#x2019;s cobas&#xae;&#x202f;c&#x202f;501-analysatorer, som er bredt anvendt p&#xe5; hospitaler og kliniske laboratorier
L&#xe6;s hele meddelelsen her: <a href="https://www.globenewswire.com/news-release/2025/08/28/3140618/0/da/ProNephro-AKI-NGAL-til-tidlig-diagnosticering-af-akut-nyreskade-er-nu-kommercielt-tilg%C3%A6ngelig-p%C3%A5-laboratorier-i-USA-gennem-BioPortos-samarbejde-med-Roche-Diagnostics.html" target="_blank" rel="noopener">ProNephro AKI(NGAL) meddelelse</a>
Disclaimer: HC Andersen Capital modtager betaling fra Bioporto for en Digital IR abonnementsaftale/Claus Thestrup 28.08.2025 - kl 14:55

HC Andersen Capital

<ul>
<li>Bioporto har modtaget den første ordre fra Roche på ProNephro AKI (NGAL) til børn og unge i USA, hvilket markerer en vigtig milepæl i kommercialiseringen af testen.</li>
<li>ProNephro AKI (NGAL) er nu officielt kommercielt tilgængelig i USA gennem samarbejdet med Roche Diagnostics, og testen er godkendt til brug på Roche's cobas c 501-analysatorer.</li>
<li>HC Andersen Capital modtager betaling fra Bioporto for en Digital IR abonnementsaftale.</li>
</ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Bioporto: ProNephro AKI™ (NGAL) kommercielt tilgængelig i USA

Summary